1,668
Views
3
CrossRef citations to date
0
Altmetric
Editorial

“B cells and autoimmunity 2016”

Pages 1-3 | Received 18 Dec 2016, Accepted 04 Jan 2017, Published online: 06 Feb 2017

References

  • Shen, P., and S. Fillatreau. 2015. Antibody-independent functions of B cells: a focus on cytokines. Nat. Rev. Immunol. 15: 441–451.
  • Braza, F., J. Chesne, S. Castagnet, et al. 2014. Regulatory functions of B cells in allergic diseases. Allergy. 69: 1454–1463.
  • Hikada, M., and M. Zouali. 2010. Multistoried roles for B lymphocytes in autoimmunity. Nat. Immunol. 11: 1065–1068.
  • Zouali, M. Tweaking the B lymphocyte compartment in autoimmune diseases. Nat Immunol. 2014. 15: 209–212.
  • Edwards, J. C., and G. Cambridge. 2001. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 40: 205–211.
  • Jonsson, R., K. A. Brokstad, P. E. Lipsky, and M. Zouali. 2001. B-lymphocyte selection and autoimmunity. Trends Immunol. 22: 653–654.
  • Zouali, M., and G. Tsay. 2016. Developing connections amongst B lymphocytes and deregulated pathways in autoimmunity. Mol. Med. 22.
  • DeFranco, A. L. 2016. Germinal centers and autoimmune disease in humans and mice. Immunol. Cell Biol. 94: 918–924.
  • Zouali, M., R. Jefferis, and A. Eyquem. 1984. IgG subclass distribution of autoantibodies to DNA and to nuclear ribonucleoproteins in autoimmune diseases. Immunology. 51: 595–600.
  • Heinlen, L. D., M. T. McClain, J. Merrill, et al. 2007. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 56: 2344–2351.
  • Khamashta, M., J. T. Merrill, V. P. Werth, et al. 2016. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis.
  • Teruel, M., and M. E. Alarcon-Riquelme. 2016. The genetic basis of systemic lupus erythematosus: What are the risk factors and what have we learned. J. Autoimmun. 74: 161–175.
  • Hasler, P., and M. Zouali. 2001. B cell receptor signaling and autoimmunity. FASEB J. 15: 2085–2098.
  • Selmi, C., J. G. Barin, and N. R. Rose. 2016. Current trends in autoimmunity and the nervous system. J. Autoimmun. 75: 20–29.
  • Viau, M., and M. Zouali. 2005. B-lymphocytes, innate immunity, and autoimmunity. Clin. Immunol. 114: 17–26.
  • Fan, X., and A. Y. Rudensky. 2016. Hallmarks of tissue-resident lymphocytes. Cell. 164: 1198–1211.
  • Intini, G., Y. Katsuragi, K. L. Kirkwood, and S. Yang. 2014. Alveolar bone loss: mechanisms, potential therapeutic targets, and interventions. Adv. Dent. Res. 26: 38–46.
  • Brito-Zeron, P., X. Bosch, M. Ramos-Casals, and J. H. Stone. 2016. IgG4-related disease: advances in the diagnosis and treatment. Best Pract. Res. Clin. Rheumatol. 30: 261–278.
  • Kinzel, S., and M. S. Weber. 2016. B Cell-directed therapeutics in multiple sclerosis: rationale and clinical evidence. CNS Drugs. 30: 1137–1148.
  • Uzzan, M, J. F. Colombel, A. Cerutti, et al. 2016. B cell-activating factor (BAFF)-targeted B cell therapies in inflammatory bowel diseases. Dig. Dis. Sci. 61: 3407–3424.
  • Dorner, T., and P. E. Lipsky. 2016. Beyond pan-B-cell-directed therapy – new avenues and insights into the pathogenesis of SLE. Nat. Rev. Rheumatol. 12: 645–657.
  • Rosenberg, A. S., A. R. Pariser, B. Diamond, et al. 2016. A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins. Clin. Immunol. 165: 55–59.
  • Hiepe, F., and A. Radbruch. 2016. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat. Rev. Nephrol. 12: 232–240.
  • Zouali, M. 2014. Transcriptional and metabolic pre-B cell receptor-mediated checkpoints: Implications for autoimmune diseases. Mol. Immunol. 62: 315–320.
  • Sakkas, L. I., and D. P. Bogdanos. 2016. Systemic sclerosis: new evidence re-enforces the role of B cells. Autoimmun. Rev. 15: 155–161.
  • Guptill, J. T, M. Soni, and M. N. Meriggioli. 2016. Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis. Neurotherapeutics. 13: 118–131.
  • Dumoitier, N., B. Terrier, J. London, et al. 2015. Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. Autoimmun. Rev. 14: 996–1004.
  • Froissart, A., A. Veyradier, M. Hie, et al. 2015. Rituximab in autoimmune thrombotic thrombocytopenic purpura: a success story. Eur. J. Intern. Med. 26: 659–665.
  • Mauri, C., and M. Menon. 2015. The expanding family of regulatory B cells. Int. Immunol. 27: 479–486.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.